Mylan Bags Meda AB on the Second Try

by | Feb 18, 2016 8:00 am | Pharmaceuticals

The pharmaceutical M&A sector has gotten very quiet in February, with just five deals announced as of Feb. 17. Compared with the 11 announced in January 2016 and 13 announced in February 2015, deal making has definitely slowed down. So it was good news to hear that Mylan NV (NASDAQ: MYL) agreed to pay $9.9 billion, including debt, to acquire Swedish generic drug maker Meda AB (STO: MEDA). Back in 2014, when Mylan was still based in the United States and known as Mylan, Inc., it made an unsuccessful run at Meda. Of course, late last year it carried on an all-out hostile takeover battle for Perrigo Company (NYSE: PRGO) that proved unsuccessful in the end. This time around, the Meda... Read More »

Biggest Health Care Deals in January 2016

by | Feb 4, 2016 8:00 am | Behavioral Health Care, Laboratories, MRI & Dialysis, Pharmaceuticals

The pace of health care mergers and acquisitions slowed considerably in January 2016. In part, that’s due to the rush to get business off the books by the end of the calendar year, which is why fourth quarters are usually so busy. This year we’ve counted about 95 transactions announced in January, which is 32% lower than December 2015’s total, and 29% below January 2014. Thanks to Shire plc’s (NASDAQ: SHPG) $32 billion deal for Baxalta Inc. (NYSE: BXLT), spending in the month handily beat those previous months. But who would’ve thought a behavioral health care deal would rank as the month’s second largest deal? Check out the chart below. We’ll have... Read More »

2015 Health Care M&A Beats All Records

by | Jan 28, 2016 2:55 pm | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

It’s déjà vu all over again. 2014 was a record-breaker for health care M&A, with 1,317 transactions and spending at an astronomical $387 billion. Then 2015 came and went and, once again, we’re writing about a record-breaking number of transactions, 1,460 currently, and astronomical spending of $563 billion. Read More »
Nestlé Health Buys into Microbiome Therapy

Nestlé Health Buys into Microbiome Therapy

by | Jan 15, 2016 9:24 pm | Pharmaceuticals

Nestlé Health Science, a subsidiary of Nestlé (NESN.VX), added to its portfolio of nutrition solutions, diagnostics, devices and drugs last week. The company paid $120 million to Seres Therapeutics (NASDAQ: MCRB) to develop and commercialize its product candidates now in development for the treatment of clostridium difficile (c-diff) infection and inflammatory bowel disease (IBD), outside the United States and Canada. The agreement supports the expansion of Seres’ portfolio in markets outside of the United States and Canada and gives financial support for its ongoing R&D. Seres retains full commercial rights to its entire portfolio of product candidates in the United States and... Read More »
This January Is Pharma M&A Month

This January Is Pharma M&A Month

by | Jan 14, 2016 9:37 pm | Pharmaceuticals

Halfway through the month of January 2016, 12 pharmaceutical deals have been announced, with a total of  $32.8 billion. You might think that’s a result of the annual JP Morgan Healthcare Summit that’s held every year in the second week of January.  That’s only half right. Last year, only nine pharma deals were announced the entire month of January, with six of them in the first two weeks. In 2014, there were 14 pharma deals in January, 11 of which were announced in the first two weeks. The biggest deal in the sector this month, Shire plc’s (NASDAQ: SHPG) $32 billion acquisition of Baxalta Inc. (NYSE: BXLT), was in the works long before the Summit, however. Shire... Read More »